Oral Aripiprazole Open-Label Rollover Study
An Open- Label Rollover Study for Subjects With Schizophrenia Completing ABILIFY® (Aripiprazole) Clinical Study 31-03-241
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Buenos Aires, Argentina
- Study site
-
Mendoza, Argentina
- Study site
-
-
-
-
-
Split, Croazia
- Study site
-
-
-
-
-
Moscow, Federazione Russa
- Study site
-
Rostov-on-Don, Federazione Russa
- Study site
-
St.Petersburg, Federazione Russa
- Study site
-
Yaroslavl, Federazione Russa
- Study site
-
-
-
-
-
Hyderabad, India
- Study site
-
Ludhiana, India
- Study site
-
Mumbai, India
- Study site
-
Tamilnadu, India
- Study site
-
-
-
-
-
Belgrade, Serbia
- Study site
-
Novi Sad, Serbia
- Study site
-
-
-
-
-
Kharkiv, Ucraina
- Study site
-
Kiev, Ucraina
- Study site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Subjects with a confirmed Axis I Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia who must have completed Otsuka study 31-03-241 (NCT00102518) treatment of adolescent subjects with schizophrenia
Exclusion Criteria:
- Patients with a co-morbid serious, uncontrolled systemic illness
- Patients with a significant risk of committing suicide
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Oral Aripiprazole
Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
|
Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
Lasso di tempo: Up to 72 months
|
An AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a subject. Change in clinical relevance (severity increased) was entered as a new AE in the current trial. Abnormal laboratory test findings were considered AEs if, in the opinion of the investigator, they represented an abnormal (clinically significant) change from baseline for that individual subject. An AE was considered serious if it was fatal; life-threatening; persistently or significantly disabling or incapacitating; required in-patient hospitalization or prolonged hospitalization; a congenital anomaly/birth defect; or other medically significant event that, based upon appropriate medical judgment, may have jeopardized the subject and may have required medical or surgical intervention. Additional information about Adverse Events can be found in the Adverse Event section. |
Up to 72 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in Clinical Global Impression Severity of Illness (CGI-S) Score
Lasso di tempo: Baseline, Last Visit (Up to 72 Months)
|
The rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. A negative change from Baseline indicated improvement |
Baseline, Last Visit (Up to 72 Months)
|
|
Number of Participants With Clinical Significant Laboratory Tests
Lasso di tempo: Baseline, Up to 72 Months
|
Blood was collected for Fasting clinical laboratory tests (serum chemistry and hematology) at Baseline, Months 12, 24, 36, 48, 60, and 72 and were analyzed at a central laboratory. Clinically significant values are defined as the following: Bilirubin, total ≥ 2.0 mg/dL. Creatine phosphokinase > 500 U/L for participants 13-17 years or 3 times the upper limit of normal for participants ≥ 18 years [Reference Range (0 to 190 IU/L (females) and 0 to 235 IU/L (males)]. Eosinophils ≥ 10 %. Hematocrit < 30 % for participants 13-17 years old or ≥ 18 year old participants female ≤ 32 % and a 3 point decrease from baseline or male ≤ 37 % and a 3 point decrease from baseline. Hemoglobin female ≤ 9.5 g/dL or male ≤ 11.5 g/dL. Prolactin > 1 times the upper limit of normal [Reference range: 2 to 18 ng/mL (males) and 3 to 30 ng/mL (females)]. |
Baseline, Up to 72 Months
|
|
Number of Participants With Clinically Significant Heart Rate
Lasso di tempo: Baseline, Up to 72 months
|
Heart rate was measured at Baseline and at each visit supine (lying on the back) and standing.
A heart rate increase is an increase of ≥ 15 beats per minute (bpm) compared to Baseline.
A heart rate decrease is a decrease of ≥ 15 bpm compared to Baseline.
|
Baseline, Up to 72 months
|
|
Number of Participants With Clinically Significant Blood Pressure
Lasso di tempo: Baseline, Up to 72 months
|
Systolic and Diastolic blood pressure was measured at Baseline and at all visits supine (lying on the back) and standing. Systolic increase was an increase of ≥ 20 mm Hg compared to Baseline and systolic decrease was a decrease of ≥ 20 mm Hg compared to Baseline. A diastolic increase was an increase of ≥ 15 mm Hg compared to Baseline and a diastolic decrease was a decrease of ≥ 15 mm Hg compared to Baseline. |
Baseline, Up to 72 months
|
|
Number of Participants With Clinically Abnormal Changes in Electrocardiograms (ECGs) Evaluations
Lasso di tempo: Baseline, Up to 72 months
|
A 12-lead ECG was recorded at Baseline, Months 6, 12, 24, 36, 48, 60 and 72. Three readings taken 5 minutes were read by a central ECG reading service and averaged. Clinically significant ECGs were defined as: Sinus Bradycardia: ≤ 50 beats per minute (bpm), decrease of ≥ 15 bpm from Baseline. Supraventricular premature beat: ≥ 2 per 10 seconds, increase from Baseline. Ventricular premature beat: ≥ 1 per 10 seconds, increase from Baseline. Right bundle branch block: present. Other intraventricular block: QRS ≥ 0.10 seconds for age 13-17 years or QRS ≥ 0.11 seconds for age ≥ 18 years, an increase of ≥ 0.02 seconds from Baseline. Symmetrical T-wave inversion: present. QTcB (QT interval corrected Bazett's formula), QTcF (QT interval corrected Fridericia's formula), QTcN (QT corrected FDA Neuropharmacology Division formula), QTcE (QT corrected fractional exponent correction method: ≥ 420 msec for age 13-17 years or ≥ 450 msec for age ≥ 18 years, ≥ 10 % increase from Baseline. |
Baseline, Up to 72 months
|
|
Number of Participants Showing Significant Weight Gain or Loss
Lasso di tempo: Baseline, Up to 72 months
|
Weight was measured at Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, and 72.
A clinically significant weight gain was defined as a ≥ 7 % increase from Baseline.
A clinically significant Weight loss was defined as a ≥ 7% decrease from Baseline.
|
Baseline, Up to 72 months
|
|
Number of Participants Experiencing Suicidal Ideation or Suicidal Behavior Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
Lasso di tempo: Baseline, Up to 72 months
|
The C-SSRS consisted of a baseline evaluation (completed at the first scheduled visit upon approval of protocol Amendment 3) that assessed the lifetime experience of the participant with suicide events and suicidal ideation and a post-baseline evaluation at each visit that focused on suicidality since the last trial visit.
Some questions are yes/no and some are on a scale of 1 (low severity) to 5 (high severity).
The number of participants experiencing suicidal ideation or suicidal behavior is reported.
|
Baseline, Up to 72 months
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disordini mentali
- Spettro della schizofrenia e altri disturbi psicotici
- Schizofrenia
- Effetti fisiologici delle droghe
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Depressori del sistema nervoso centrale
- Agenti antipsicotici
- Agenti tranquillanti
- Psicofarmaci
- Agenti serotoninergici
- Agenti antidepressivi
- Agonisti della dopamina
- Agenti dopaminergici
- Agonisti del recettore della serotonina 5-HT1
- Agonisti del recettore della serotonina
- Antagonisti del recettore della serotonina 5-HT2
- Antagonisti della serotonina
- Antagonisti del recettore della dopamina D2
- Antagonisti della dopamina
- Aripiprazolo
Altri numeri di identificazione dello studio
- 31-05-243
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .